Formulation: A solid
Formal Name: (S)-N1-((6S,9S,12S,15S,18S,24S,27S,30S,33S,36R,39S,42S,45S,49S,53S,56S)-39-((1H-indol-3-yl)methyl)-1,60-diamino-12,15-bis(4-aminobutyl)-33-benzyl-56-formyl-9,18,30,42-tetrakis(3-guanidinopropyl)-49,53-bis(hydroxyamino)-24,45-bis(4-hydroxybenzyl)-1-imino-27-isopropyl-36-(mercaptomethyl)-7,10,13,16,19,22,25,28,31,34,37,40,43,46,47,50,51,54-octadecaoxo-2,8,11,14,17,20,23,26,29,32,35,38,41,44,55-pentadecaazahexacontan-6-yl)-2-((S)-5-guanidino-2-((S)-5-guanidino-2-((S)-5-guanidino-2-(hydroxyamino)pentanamido)pentanamido)pentanamido)pentanediamide, trifluoroacetate salt
Purity: ≥98%
Formula Markup: C127H206N50O29S • XCF3COOH
Formula Weight: 2929,4
Shelf life (days): 1460
Notes: TRPV1-Tat is a peptide antagonist of transient receptor potential vanilloid 1 (TRPV1).{72068} It consists of amino acids 736-745 from the A-kinase anchor protein (AKAP)-binding domain of TRPV1 and the cell-penetrating peptide sequence from HIV Tat. TRPV1-Tat (200 µM) inhibits currents induced by heat or phorbol 12-myristate 13-acetate (PMA; Item No. 10008014) in whole-cell patch-clamp assays using primary mouse dorsal root ganglia. It increases the hind paw mechanical pain threshold in rats when administered at the doses 10 or 30 µM.{72069}
English
Deutsch
